HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system

References

• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46:894-921
   PubMed Web of Science ®Google Scholar
• Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005;57:1215-20
   PubMed Web of Science ®Google Scholar
• Minde K, Lewin D, Weiss G, et al. The hyperactive child in elementary school: a 5 year, controlled, follow-up. Except Child 1971;38:215-21
   PubMed Web of Science ®Google Scholar
• Adesman AR The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Prim Care Companion J Clin Psychiatry 2001;3:66-7
   PubMedGoogle Scholar
• Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 2007;32:631-42
   PubMed Web of Science ®Google Scholar
• Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59(Suppl. 7):S4-16
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996;53:437-46
   PubMed Web of Science ®Google Scholar
• Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-77
   PubMed Web of Science ®Google Scholar
• Johnston C, Mash EJ Families of children with attention-deficit/hyperactivity disorder: review and recommendations for future research. Clin Child Fam Psychol Rev 2001;4:183-207
   PubMed Web of Science ®Google Scholar
• Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003;42:1415-23
   PubMed Web of Science ®Google Scholar
• Designating September 7, 2004, as ‘National Attention Deficit Disorder Day.’ S Res 370, 108th Cong, 2nd Session (2004)
   Google Scholar
• Daytrana® [package insert]. Wayne, Pa: Shire US Inc; 2007
   Google Scholar
• Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-57
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44
   PubMed Web of Science ®Google Scholar
• Robison LM, Sclar DA, Skaer TL, et al. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin Pediatr 1999;38:209-17
   PubMed Web of Science ®Google Scholar
• Noven Pharmaceuticals Inc. DOT Matrix® Technology. Shire US Inc.: Wayne, PA. Available at: http://www.daytrana.com [Last accessed 3 January 2008]
   Google Scholar
• Heal DJ, Pierce DM Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20:713-38
   PubMed Web of Science ®Google Scholar
• Wilens TE, Boellner SW, López FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47:700-8
   PubMed Web of Science ®Google Scholar
• Pelham WE, Manos MJ, Ezzell CE, et al. A dose-ranging study of a methylphenidate transdermal system in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:522-9
   PubMed Web of Science ®Google Scholar
• Pelham WE, Burrows-Maclean L, Gnagy EM, et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Exp Clin Psychopharmacol 2005;13:111-26
   PubMed Web of Science ®Google Scholar
• McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006;9:476-85
   PubMedGoogle Scholar
• Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008;69:149-59
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Schacht A, Dittmann RW, et al. Global impression of perceived difficulties in children and adolescents with attention-deficit/hyperactivity disorder: reliability and validity of a new instrument assessing perceived difficulties from a patient, parent and physician perspective over the day. Child Adolesc Psychiatry Ment Health 2008;2:10
   PubMedGoogle Scholar
• Saylor K, Buermeyer C, Sutton V, et al. The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder–Child Version: psychometric properties of an adaptive change instrument. J Child Adolesc Psychopharmacol 2007;17:831-42
   PubMed Web of Science ®Google Scholar
• Varni JW, Burwinkle TM The PedsQL as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: a population-based study. Health Qual Life Outcomes 2006;4:26
   PubMed Web of Science ®Google Scholar
• Rentz AM, Matza LS, Secnik K, et al. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder. Qual Life Res 2005;14:719-34
   PubMed Web of Science ®Google Scholar
• Landgraf JM, Rich M, Rappaport L. Measuring quality of life in children with attention-deficit/hyperactivity disorder and their families: development and evaluation of a new tool. Arch Pediatr Adolesc Med 2002;156:384-91
   PubMed Web of Science ®Google Scholar
• Bastiaens L. Both atomoxetine and stimulants improve quality of life in an ADHD population treated in a community clinic. Psychiatr Q 2008;79:133-7
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Dittmann RW, Schacht A, et al. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study. J Child Adolesc Psychopharmacol 2007;17:813-30
   PubMed Web of Science ®Google Scholar
• Prasad S, Harpin V, Poole L, et al. The SUNBEAM Study Group. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23:379-94
   PubMed Web of Science ®Google Scholar
• Perwien AR, Kratochvil CJ, Faries DE, et al. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?. J Child Adolesc Psychopharmacol 2006;16:713-24
   PubMed Web of Science ®Google Scholar
• Brown RT, Perwien A, Faries DE, et al. Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. Clin Pediatr (Phila) 2006;45:819-27
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006;10:92-111
   PubMedGoogle Scholar
• Dunlop WP, Cortina JM, Vaslow JB, et al. Meta-analysis of experiments with matched groups or repeated measures designs. Psychological Methods 1996;1:170-7
   Web of Science ®Google Scholar
• Manassis K. When attention-deficit/hyperactivity disorder co-occurs with anxiety disorders: effects on treatment. Exp Rev Neurotherapeut 2007;7:981-8
   PubMedGoogle Scholar
• Biederman J, Quinn D, Weiss M, et al. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs 2003;5:833-41
   PubMedGoogle Scholar
• Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:883-92
   PubMed Web of Science ®Google Scholar